"N-of-1" single participant trials of 4-aminopyridine (4-AP) as precision therapy for the treatment of neurologic manifestations associated with KCNA1 (Kv1.1) and KCNA2 (Kv1.2) epilepsies.

Authors
Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Register
Year 2024
This article has no abstract
Epistemonikos ID: fdd21115e862c624492132f13de4db77e54f5dc7
First added on: Mar 18, 2025